- Motley Fool•6 days ago
Industry Focus examines a few stocks that benefit from the 21st Century Cures Act.
- Reuters•8 days ago
BioMarin Pharmaceutical Inc announced on Sunday what it called "positive interim results" from its study of a gene therapy treatment for severe hemophilia. The company said the average annualized ...
- PR Newswire•8 days agoBioMarin to Provide Update to Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A at 35th Annual J.P. Morgan Healthcare Conference
SAN RAFAEL, Calif., Jan. 8, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today an update to its positive interim results of an open-label Phase 1/2 study of BMN 270, an investigational ...
BMRN : Summary for BioMarin Pharmaceutical Inc. - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||75.43 x 100|
|Ask||88.49 x 200|
|Day's Range||86.07 - 88.13|
|52 Week Range||62.12 - 102.49|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-29.33|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|